Accelerated coronary disease in the cardiac allograft (TxCAD) is a major complication affecting long-term survival of heart transplant patients. Since the transplanted heart remains denervated, the first sign of TxCAD may be silent myocardial infarction or sudden death. The prevalence of this disease has been unaltered since the advent of cyclosporine immunosuppression. Serial annual coronary arteriograms in 132 patients undergoing transplantation after 1979 at Stanford revealed 44 patients who developed TxCAD (33%). Multiple variables, including patient lipid profile, extent of donor and recipient tissue match, age of recipient and donor, number of rejection episodes, prednisone dose, and fasting blood sugar were examined in relation to occurrence of TxCAD. Donor age was greater among the 44 patients developing TxCAD that in the 88 patients who did not develop coronary artery disease (23.5 ± 5.8 vs 21.3 ± 5.7 years, p < .05). The fasting plasma triglyceride level 1 year after transplantation was 236.0 ± 246.3 mg% in the patients with TxCAD vs 170.1 ± 108.2 mg% in those without TxCAD (p < .05). No other indexes, including number of rejection episodes during first posttransplant year, number of HL-A mismatches, level of maintenance steroids, fasting blood sugar, and cholesterol subfractions identified patients who developed TxCAD. We conclude that TxCAD has limited correlation with the clinical and laboratory factors analyzed. Higher donor age and elevated plasma triglycerides may be significant predisposing factors for the development of TxCAD. Circulation 76(suppl V), V-56, 1987. 
THE DEVELOPMENT of accelerated coronary artery disease in the cardiac allograft (TxCAD) is one of the major causes of graft failure in long-term survivors after cardiac transplantation and of subsequent patient morbidity and mortality. Four hundred heart transplant procedures were performed in 368 patients, and 30 heart-lung transplant procedures were performed in 29 patients, at Stanford University Medical Center by the end of 1985. The 1 year heart transplant actuarial survival rate increased from 22% in 19691 to 83.4% in 1985. Early mortality, generally resulting from infectious complications and acute rejection, has decreased significantly. However, with more long-term survivors, TxCAD has become an increasingly important problem. In our institution, 20 of 34 cardiac retransplant procedures (58.8%), including two third heart transplantations, have been performed because of severe TxCAD.2 Serial coronary arteriography is essential for diagnosis of TxCAD because the cardiac allograft remains denervated and patients do not experience typical angina pectoris. The first clinical signs of TxCAD are often development of congestive heart failure, ventricular arrhythmias, silent myocardial infarction detected on the electrocardiogram, or, frequently, sudden death.
In spite of many investigations into this problem,4-6 the pathogenesis of TxCAD remains undetermined and has resisted several potential prophylactic therapies.
The purpose of this study was (1) to analyze the relationship of known coronary artery disease risk factors to the development of TxCAD, and (2) to assess the relationship between plasma lipid levels and the incidence of TxCAD.
Materials and methods
The patient data base consisted of 185 consecutive heart transplant patients undergoing operation between January 1979 and December 1984 (including 22 heart-lung transplant patients). A total of 132 of these patients survived at least 1 year after transplant and had had annual coronary arteriograms. The 132 long-term survivors were divided into two groups: the first group (Tx no CAD group) consisted of 88 patients who had undergone heart transplantation at least 1 year previously and CIRCULATION V-56 CARDIAC TRANSPLANTATION had no evidence of TxCAD on any yearly coronary arteriogram.
The mean follow-up was 2.3 years (1 to 5 years). The second group (TxCAD group) consisted of 44 patients who had undergone heart transplantation at least 1 year before and had documented TxCAD by arteriography. Their mean follow-up was 2.6 years (1 to 5 years).
All patients were managed with standard immunosuppressive regimens including prednisone and azathioprine from January 1979 to November 1980 and prednisone and cyclosporine from December 1980 to December 1984. The cyclosporine trough serum levels were adjusted to 50 to 150 ng/dl by radioimmunnoassay technique at approximately 2 to 3 months after the transplant procedure. Additionally, all patients were treated from the first postoperative week with an antiplatelet regimen consisting of aspirin, 80 mg every day and dipyridamole, 75 mg tid. Antirejection therapy, when indicated, consisted of increased corticosteroid dose and, in refractory cases, administration of rabbit antithymocyte globulin. Potential All patients were evaluated annually with standard right and left heart catheterization and selective coronary arteriography by the percutaneous femoral approach. Left ventricular cineangiography was performed in all patients and cardiac output was determined by the Fick method. The procedures for cardiac catheterization were explained to all patients and informed consent was obtained under Stanford Institutional Review Board guidelines.
Criteria for diagnosis of TxCAD. Based on review of all arteriograms any evidence of coronary disease, whether in proximal major segments or in distal branches, was considered abnormal. Often the arteriogram obtained 1 year after transplantation provided a basis for noting small changes on subsequent annual arteriograms. Two types of abnormalities have been observed. One category (type A) is characterized by discrete or tubular stenoses located primarily in the proximal and midportions of major coronary vessels, similar in appearance and distribution to lesions observed in patients with ordinary atherosclerotic coronary disease. A second category of disease (type B) is characterized by diffuse concentric narrowing of vessels, with either abrupt onset of the narrowing or gradual tapering of the distal branches. Often these narrowed vessels are irregular, poorly visualized, and have interval occlusion of small branches or exhibit distal obliteration. Typical coronary artery changes are shown in figure 1 .
The morphology of the coronary arterial lesions was interpreted by two angiographers and a consensus was reached. 
Results
The overall incidence of TxCAD in heart transplant recipients who survived at least 1 year after transplantation in the Stanford heart transplant program was 81 of 221 (36.2%) before 1985, as shown in table 1. The Tx no CAD group reported here consists of the 88 heart transplant patients who had surgery from 1979 to 1984 with subsequent normal yearly coronary arteriograms. The TxCAD group consists of the 44 heart transplant patients with abnormal coronary arteriograms who underwent operation during the same time period. Potential prospective coronary risk factors were compared in the two groups, as shown in table 2. Recipient age, number of HL-A mismatches, dose of prednisone, and incidence of rejection during the first posttransplant year were similar in these two groups. The mean donor age of the patients in the TxCAD group (23.5 years) was older than the mean donor age of those in the Tx (27.3%) patients whose original cardiac disease was coronary artery disease, whereas in the TxCAD group, the incidence of prior coronary artery disease was higher (16 of 44, 36.4%), but the difference did not reach statistical significance. Twenty-two of 73 patients (30%) with cardiomyopathy in their original heart developed coronary artery disease in the allograft.
Laboratory data for the two groups are listed in tables 4, 5, and 6. The mean values of total plasma cholesterol, plasma triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, very low-de'nsity lipoprotein cholesterol, and fasting blood sugar measured annually after transplant did not reveal significant differences between the Tx no CAD and TxCAD groups. Patients with TxCAD had higher levels of plasma triglycerides at 1 year after the transplant procedure than did those in the Tx no CAD group (236 ±-39.4 mg/dl in TxCAD group vs 170.1 ±-F 11.8 mg/dl in Tx no CAD group, p < .05). Plasma triglyc- Those patients who had coronary artery disease that was limited entirely to one morphologic type (either type A or B) were compared. Table 7 shows that those patients with type B disease (generally distal, concentric, occlusive with distal pruning) had significantly higher total cholesterol and triglyceride blood levels than did patients with type A disease (proximal and midvessel discrete stenosis). The association of the diffuse concentric distal disease with higher triglyceride levels was associated with an elevation of the lowdensity lipoprotein cholesterol level; however, statistical significance was not reached because of the relatively small number of patients in each group.
Discussion
The incidence of accelerated coronary artery disease in Stanford heart transplant patients remains high despite multiple therapeutic regimens. A routine prophylactic antiplatelet regimen consisting of dipyridamole and aspirin was originally thought to retard the development of TxCAD. 0 However, this regimen is insufficient, if effective at all. Lurie et al.1' did report the use of dipyridamole in an experimental preparation of transplantation in the rat heart receiving cyclosporine immunosuppression and demonstrated complete prevention of the atherosclerosis-like intramural coronary vessel disease at 20 to 50 days after transplant. The relevance of this preparation to human TxCAD, however, is not clear, and this treatment obviously has not proved to be as effective in human heart transplant recipients, as noted above. Cyclosporine has been used as the major immunosuppressive agent for heart transplantation since 1980 at Stanford. Comparison of patients treated with conventional immunosuppressives (azathioprine and prednisone) and those treated with the cyclosporine regimen (cyclosporine and prednisone) did not show significant differences in the incidence of TxCAD. 12 This is disappointing, since it had been hoped that more effective immunosuppression with cyclosporine might prevent TxCAD.
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The relationship between the type of initial cardiac disease and the development of TxCAD is controversial. Griepp et al.'`did not show a difference in the incidence of TxCAD between patients whose underlying disease was coronary artery disease and those with idiopathic cardiomyopathy. In contrast, pathologic examination of explanted hearts at the time of retransplantation showed that heart transplant patients with coronary artery disease in their original heart were more likely to come to retransplantation for TxCAD than those with normal coronary vessels before transplantation.'3 In our study, CAD was the underlying disease in 24 of 88 (27.3%) patients in the Tx no CAD group and in 16 of 44 (36.5%) of those in the TxCAD group. These results reveal a tendency for patients who develop TxCAD to have prior coronary artery disease, although this difference did not reach statistical significance. Average donor age was slightly older in the TxCAD group, and this risk factor has been reported previously.'
Triglyceride levels at 1 year after the transplant procedure were greater in the TxCAD group than in the Tx no CAD group. This trend was not evident in subsequent years. Most of the patients who had hypertriglyceridemia at 1 year had subsequently restricted calorie and fat intake to reduce lipid levels, and these treatments might have contributed to the subsequent drop in lipid levels. No significant differences in total cholesterol, low-density lipoprotein cholesterol, very lowdensity lipoprotein cholesterol, and high-density lipoprotein cholesterol were observed in the two groups. However, subtyping the arteriographic disease suggested a greater association of diffuse concentric distal obliterative lesions with higher triglyceride and total cholesterol levels than with the more focal discrete disease located in proximal and middle portions of vessels. It appears that hypertriglyceridemia may be a contributing factor in the development of TxCAD in heart transplant recipients, but we note a surprising lack of strong correlation with other measured lipid levels. No significant differences in total cholesterol, low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol were seen in the TxCAD and Tx no CAD groups. We found this lack of correlation somewhat surprising in view of the generally accepted role of elevated serum cholesterol in the probable pathogenesis of ordinary coronary artery disease. "l Accelerated atherosclerotic disease has been observed in recipients of other organ transplants.18"21 Ibels et al.'8 observed that occlusive arterial disease was responsible for 12% of the deaths in a series of 325 V-60 cadaveric renal transplant recipients. Acute myocardial infarction accounted for 9% and this was calculated to be 25 times more frequent than expected in a normal population. Hyperlipoproteinemia has been reported to occur frequently in renal transplant recipients, 19 20 and this may be an important factor in the development of accelerated coronary disease in these patients .
Several reports indicate a relationship between corticosteroid therapy and abnormal lipid levels. Longterm corticosteroid therapy-induced hypertriglyceridemia has been observed in asthmatic patients. 22 Coronary atherosclerosis may be accelerated by corticosteroid therapy in patients with systemic lupus erythematosus.23 Histopathologic changes noted at autopsy in intramural coronary arteries of corticosteroidtreated patients with SLE have included fibrous intimal proliferation and endothelial cell degeneration. In our study, however, the dose of prednisone given was not significantly different in patients in the TxCAD and Tx no CAD groups and the incidence of rejection episodes during the first postoperative year was not significantly different in the two groups; a finding that is consistent with earlier reports. 10 The histopathologic changes found in patients in the TxCAD group consist of intimal proliferative lesions and atherosclerotic plaques.24 Proliferative lesions are characterized by myointimal cell proliferation, intimal fibrosis, increased ground substance, and focal disruption of the internal elastic lamella. These intimal proliferative lesions tend to predominate in the small vessels. The atherosclerotic lesions are histopathologically similar to those occurring in nontransplant coronary artery disease observed at autopsy. In contrast to nontransplant coronary artery disease, the coronary vessels tend to be affected throughout their length. The arterial intima is thickened by a diffuse endothelial cell proliferation or intimal fibroobliterative lesions causing narrowing or total occlusion. Histologically similar vascular lesions are seen sometimes in the renal vessels of kidney transplant recipients.251, 26 Tissue immunofluorescence studies of the transplanted heart show that vascular depositions of complement-fixing immunoglobin are observed in biopsy and autopsy materials. 27 These observations suggest that the pathogenesis of accelerated vascular disease in organ transplant graft may be related to immune injury, perhaps aggravated by an atherogenic environment.
In conclusion, the correlation of TxCAD with the analyzed clinical and laboratory factors is limited. Older donor age and elevated plasma triglyceride levels may be significant predisposing factors in the development of TxCAD.
